-
-
Experience of a tertiary hospital in Singapore managing a dual outbreak of COVID and dengue
Takeda2 minutes -
Case report: Acute vision loss in a young returning traveler with dengue fever
Takeda2 minutes -
Covid-19 and dengue: Double punches for dengue-endemic countries in Asia
Takeda2 minutes -
Autochthonous dengue in two Dutch visiting Département Var, Southern France (July 2020)
Takeda2 minutes -
Dengue is the most common non-malarial febrile illness in Southern Asia and Southeastern Asia
Takeda2 minutes -
When fever is not malaria in Latin America
Takeda2 minutes -
Impact of SARS-CoV-2 interventions on dengue transmission
Takeda2 minutes -
Vector control
Takeda4 minutes -
Economic Impact of Dengue
Takeda4 minutes -
Dengue global epidemiology
Takeda4 minutes -
Burden of Dengue
Takeda38 minutes -
Challenges in the management and diagnosis of Zika, Dengue and Chikungunya
Takeda42 minutes -
Managing the severely ill dengue patients – Adult and Paediatric Intensivists
ADVA92 minutes -
Clinical diagnosis and management of dengue
PAHO -
Randomised trials of Wolbachia for dengue control – a step towards elimination?
ADVA50 minutes -
Impact of the COVID-19 Pandemic on the Global Dengue Situation
ADVA79 minutes -
Global, regional, and national dengue burden from 1990 to 2017
Takeda2 minutes -
The COVID-19 pandemic should not jeopardize dengue control
Takeda2 minutes
Dengue Academy is intended for an international audience of healthcare professionals outside of the US and UK.
This website has been initiated and developed by Takeda
© Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
VV-MEDMAT-55340, Date of preparation: November 2021